Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05924_nanopub.RAPtXGWnWNFmojSvVHtKtjty-aF01icFJx1bWN6G3VsRY#assertion>. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB05924 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05924 label "NLX-P101 [drugbank:DB05924]" assertion.
- drugbank:DB05924 seeAlso DB05924 assertion.
- drugbank:DB05924 description "NLX-P101, gene therapy is developed by Neurologix to treat Parkinsonâs disease. The gene is glutamic acid decarboxylase (GAD), whose product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and targets the subthalamic nucleus (STN), which is overactive in patients with Parkinsonâs disease. NLX-P101 is being evaluated as a therapeutic drug when injected into this deep brain structure that is known to function abnormally in Parkinsonâs patients." assertion.
- drugbank:DB05924 identifier "drugbank:DB05924" assertion.
- drugbank:DB05924 title "NLX-P101" assertion.
- drugbank:DB05924 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05924 drugbank_vocabulary:drugbank-id "DB05924" assertion.
- drugbank:DB05924 bio2rdf_vocabulary:x-identifiers.org DB05924 assertion.
- drugbank:DB05924 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05924" assertion.
- drugbank:DB05924 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05924 bio2rdf_vocabulary:identifier "DB05924" assertion.